scholarly journals The Use of Ketamine as Therapy for Depression

2021 ◽  
Vol 1 (2) ◽  
pp. 28-31
Author(s):  
Lovina Lovina
Keyword(s):  
Chronic Pain ◽  
Clinical Practice ◽  
Pain Management ◽  
Mental Disorders ◽  
Arterial Pressure ◽  
Depressive Disorder ◽  
Systemic Arterial Pressure ◽  
Significant Problem ◽  
Chronic Pain Management ◽  
New Generation

Depressive disorder is still a significant problem in several developed countriesand is morbidity caused by mental disorders. With the development of science,now discovered the unique pharmacodynamic properties of ketamine, which isused as an antidepressant. As we know in clinical practice, ketamine is used foranaesthesia, analgesia, sedation, and chronic pain management. Rapid-onsetantidepressants resulted from increased levels of BDNF in the hippocampus.Extracellular glutamate agents are not new for the treatment of depression.According to the neurobiology view, depression is a monoaminergic phenomenon,so this is the impetus for discovering a new generation of antidepressants.Ketamine can be given intravenously in subanesthetic doses. Still, monitoringmust be carrying in therapy administration because of the possible side effectssuch as hypersalivation, tachycardia, increased systemic arterial pressure, andintracranial pressure.

The Use of Ketamine as Therapy for Depression

2021 ◽  
Vol 1 (2) ◽  
pp. 28-31
Author(s):  
Lovina Lovina
Keyword(s):  
Chronic Pain ◽  
Clinical Practice ◽  
Side Effects ◽  
Developed Countries ◽  
Rapid Onset ◽  
Systemic Arterial Pressure ◽  
Chronic Pain Management ◽  
Extracellular Glutamate ◽  
Treatment Of Depression ◽  
New Generation

Depressive disorder is still a significant problem in several developed countries and is morbidity caused by mental disorders. With the development of science, now discovered the unique pharmacodynamic properties of ketamine, which is used as an antidepressant. As we know in clinical practice, ketamine is used for anaesthesia, analgesia, sedation, and chronic pain management. Rapid-onset antidepressants resulted from increased levels of BDNF in the hippocampus. Extracellular glutamate agents are not new for the treatment of depression. According to the neurobiology view, depression is a monoaminergic phenomenon, so this is the impetus for discovering a new generation of antidepressants. Ketamine can be given intravenously in subanesthetic doses. Still, monitoring must be carrying in therapy administration because of the possible side effects such as hypersalivation, tachycardia, increased systemic arterial pressure, and intracranial pressure.

Hypnosis and relaxation

2013 ◽  
pp. 560-568 ◽  
Author(s):  
Christina Liossi ◽  
Leora Kuttner ◽  
Chantal Wood ◽  
Lonnie K. Zeltzer
Keyword(s):  
Chronic Pain ◽  
Clinical Practice ◽  
Pain Management ◽  
Research Evidence ◽  
Research Literature ◽  
Current Understanding ◽  
Relaxation Techniques ◽  
Chronic Pain Management ◽  
Future Studies ◽  
Hypnotic Analgesia

This chapter discusses the current research literature and clinical practice regarding the use of hypnosis in paediatric pain management, first defining hypnosis and discussing theoretical conceptualizations. Next it presents our current understanding of the mechanisms of hypnotic analgesia, along with the research evidence for the efficacy of hypnosis in the control of acute and chronic paediatric pain; in both sections relevant clinical techniques are discussed. It also includes a description and discussion of different relaxation techniques and the evidence for their efficacy in acute and chronic pain management, and concludes with an attempt to summarize and evaluate the existing literature and make suggestions for future studies and clinical practice.

Erector spinae plane block in chronic pain management: a scoping review

2021 ◽  
pp. 030089162098593
Author(s):  
Dmitriy Viderman ◽  
Antonio Sarria-Santamera
Keyword(s):  
Chronic Pain ◽  
Clinical Practice ◽  
Pain Management ◽  
Scoping Review ◽  
Case Series ◽  
Erector Spinae ◽  
Chronic Pain Management ◽  
Efficacy And Safety ◽  
Erector Spinae Plane Block

Chronic pain is reaching epidemic levels. Chronic pain represents a significant burden for patients, healthcare systems, and society, given its impact on quality of life, increased disability, and risk of hospitalization and mortality. Unmet needs of chronic pain management are also significant as only a small percentage of patients respond to medical (drug) therapy. Erector spinae plane block (ESPB) was rapidly adapted in clinical practice and numerous cases have been published assessing its effectiveness, but no systematic review of evidence on ESPB in chronic pain management is available. The purpose of this scoping review is to perform a comprehensive overview of existing evidence on ESPB in chronic pain management. We analyzed cases and case series reporting 43 patients. ESPB was performed in patients with severe pain and in all cases resulted in some degree of pain relief. However, because there was heterogeneity in mechanisms and underlying causes of chronic pain, preprocedural analgesic therapy, and pain assessment in reporting the cases, with the information currently available (case reports) we cannot make a definitive conclusion regarding efficacy and safety of ESPB in chronic pain management. Lack of homogeneity was present in medication use before the procedure, indicating a significant variation in how patients with chronic pain are managed. Variation in clinical practice can indicate the need to improve the quality of care to alleviate the chronic pain burden. Randomized controlled clinical trials are warranted to establish efficacy and safety of ESPB in chronic pain management.

scholarly journals The Beliefs and Attitudes of Cypriot Physical Therapists Regarding the Use of Deep Friction Massage

Medicina ◽  
2019 ◽  
Vol 55 (8) ◽  
pp. 472
Author(s):  
Pitsillides ◽  
Stasinopoulos
Keyword(s):  
Chronic Pain ◽  
Clinical Practice ◽  
Pain Management ◽  
Chronic Conditions ◽  
Physical Therapists ◽  
Daily Practice ◽  
Chronic Pain Management ◽  
Multiple Choice Questions ◽  
Therapeutic Results ◽  
Beliefs And Attitudes

Background: Deep friction massage (DFM) is a widely used technique by physical therapists worldwide for chronic pain management. According to Dr. James Cyriax, compliance with the proposed guidelines is vital to obtain the desired therapeutic results. Objectives: This study explored the beliefs and attitudes of Cypriot physical therapists to DFM and their compliance with the suggested guidelines to identify any empirical-based application patterns and compare them to the suggestions of Cyriax. In addition, the prevalence of DFM use in clinical practice in Cyprus was investigated. Methods: Questionnaires, consisting of 18 multiple choice questions and a table of six sub-questions, were distributed to 90 local physical therapists. Results: A total of 70% of respondents declared that they perform DFM in their daily practice. The respondents answered 11 out of the 19 technical questions in compliance with the guidelines. Conclusion: The study revealed the DFM application pattern of Cypriot physical therapists. The compliance percentage of this pattern to Cyriax guidelines was 58% in general and 62.5% for patients with chronic conditions.

Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice

2019 ◽  
Vol 20 (13) ◽  
pp. 971-982 ◽  
Author(s):  
Priscila Akemi Yamamoto ◽  
Ana Carolina Conchon Costa ◽  
Gabriela Rocha Lauretti ◽  
Natália Valadares de Moraes
Keyword(s):  
Chronic Pain ◽  
Clinical Practice ◽  
Pain Management ◽  
Pain Therapy ◽  
Adverse Reactions ◽  
Chronic Pain Management ◽  
Clinical Implementation ◽  
Drug Effectiveness ◽  
Gene Pairs ◽  
Chronic Pain Therapy

Pharmacogenomics (PGx) has emerged as an encouraging tool in chronic pain therapy. Genetic variations associated with drug effectiveness or adverse reactions (amitriptyline/nortriptyline/codeine/oxycodone/tramadol-CYP2D6, amitriptyline-CYP2C19, carbamazepine-HLA-A, carbamazepine/oxcarbazepine-HLA-B) can be used to guide chronic pain management. Despite this evidence, many obstacles still need to be overcome for the effective clinical implementation of PGx. To translate the pharmacogenetic testing into actionable clinical decisions, the Clinical Pharmacogenetics Implementation Consortium has been developing guidelines for several drug–gene pairs. This review will show the applicability of PGx in chronic pain from disease to treatment; report the drug–gene pairs with strongest evidences in the clinic; and the challenges for the clinical implementation of PGx.

Sign in / Sign up

Export Citation Format

Share Document